|
2020 Conference Publication Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 YearsCelius, Elisabeth G., Oh, Jiwon, Achiron, Anat, Compston, D. Alastair S., Devonshire, Virginia, Hellwig, Kerstin, Hutton, George J., McCombe, Pamela, Moore, Marie, Simm, Renata Faria, Sousa, Livia, Vincent, Stephen G., Chung, Luke, Daizadeh, Nadia, Mitchell, Colin and Rog, David (2020). Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April - 1 May 2020. Philadelphia, PA United States: Lippincott Williams & Wilkins. |
|
2019 Conference Publication Aggressive form of multiple sclerosis can be predicted early after disease onsetMalpas, C. B., Manouchehrinia, A., Sharmin, S., Roos, I., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand'Maison, F., Ozakbas, S., Van Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H. ... Kalincik, T. (2019). Aggressive form of multiple sclerosis can be predicted early after disease onset. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2019 Conference Publication Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosisSharmin, S., Lefort, M., Andersen, J., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Butzkueven, H., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand'Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F. ... Kalincik, T. (2019). Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis. 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, Sep 11-13, 2019. LONDON: SAGE PUBLICATIONS LTD. |
|
2019 Conference Publication Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study dataBovis, F., Kalincik, T., Lublin, F., Cutter, G., Malpas, C., Horakova, D., Havrdova, E. Kubala, Trojano, M., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Izquierdo, G., Eichau, S., Patti, F., Terzi, M., Grammond, P., Bergamaschi, R., Sola, P., Ferraro, D., Ozakbas, S., Iuliano, G., Boz, C., Hupperts, R., Grand'Maison, F., Oreja-Guevara, C., Van Pesch, V., Cartechini, E. ... Sormani, M. P. (2019). Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2019 Conference Publication Modifiers of the effectiveness of MS immunotherapiesKalincik, T., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand'Maison, F., Sola, P., Ferraro, D., Shaygannejad, V., Alroughani, R., Hupperts, R., Terzi, M., Boz, C., Lechner-Scott, J., Cartechini, E., Van Pesch, V., Iuliano, G., Granella, F., Bergamaschi, R., Bolanos, R. F. ... Butzkueven, H. (2019). Modifiers of the effectiveness of MS immunotherapies. 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, Sep 11-13, 2019. LONDON: SAGE PUBLICATIONS LTD. |
|
2019 Conference Publication Predicting long-term sustained disability progression in multiple sclerosisSharmin, S., Malpas, C., Horakova, D., Havrdova, E. K., Izquierdo, G., Eichau, S., Trojano, M., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Terzi, M., Hupperts, R., Alroughani, R., Boz, C., Shaygannejad, V., Van Pesch, V., Cartechini, E., Kappos, L., Lechner-Scott, J., Bergamaschi, R., Turkoglu, R., Solaro, C., Ramo-Tello, C. ... Kalincik, T. (2019). Predicting long-term sustained disability progression in multiple sclerosis. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2019 Conference Publication Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progressionDe Brouwer, E., Peeters, L., Becker, T., Altintas, A., Soysal, A., Van Wijmeersch, B., Boz, C., Oreja-Guevara, C., Gobbi, C., Solaro, C., Ramo, C., Spitaleri, D. L., Maimone, D., Aguera-Morales, E., Cartechini, E., Butler, E., Havrdova, E., Patti, F., Granella, F., Grand'Maison, F., Moore, F., Verheul, F., Iuliano, G., Butzkueven, H., Lechner-Scott, J., Kuhle, J., Sanchez Menoyo, J. L., Rojas, J. I., Prevost, J. ... Moreau, Y. (2019). Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2019 Conference Publication Determinants of therapeutic lag in relapsing multiple sclerosisRoos, I., Frascoli, F., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Patti, F., Prat, A., Girard, M., Duquette, P., Onofr, M., Lugaresi, A., Grammond, P., Ozakbas, S., Sola, P., Ferraro, D., Bergamaschi, R., Cartechini, E., Sa, M. J., Boz, C., Grand'Maison, F., Lechner-Scott, J., Terzi, M., Granella, F., Alroughani, R., Iuliano, G., Hupperts, R., Spitaleri, D. ... Kalincik, T. (2019). Determinants of therapeutic lag in relapsing multiple sclerosis. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2019 Conference Publication Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study)Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H. -P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study). 5th Congress of the European-Academy-of-Neurology (EAN), Oslo Norway, Jun 29-Jul 02, 2019. HOBOKEN: WILEY. |
|
2019 Conference Publication Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC studySprenger, T., Lebrun-Frenay, C., Vermersch, P., Park, M. S., Chinchilla, D., McCombe, P., Lincoln, J., Bergsland, N., Dwyer, M., Kappos, L., Cavalier, S., Roesch, N., Guce, M., Poole, E. and Zivadinov, R. (2019). Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study. 5th Congress of the European-Academy-of-Neurology (EAN), Oslo Norway, Jun 29-Jul 02, 2019. HOBOKEN: WILEY. |
|
2019 Conference Publication Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC StudySprenger, Till, Lebrun-Frenay, Christine, Vermersch, Patrick, Park, Min Su, Chinchilla, Dennis, McCombe, Pamela, Lincoln, John, Kappos, Ludwig, Bergsland, Niels, Dwyer, Michael, Cavalier, Steven, Roesch, Nora, Somera-Molina, Kathleen, Poole, Elizabeth and Zivadinov, Robert (2019). Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2019 Conference Publication Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)Pelletier, Daniel, Arnold, Douglas L., Boyko, Alexey N., Comi, Giancarlo, Hartung, Hans-Peter, Havrdova, Eva Kubala, Inshasi, Jihad Said, McCombe, Pamela, Nakamura, Kunio, Oreja-Guevara, Celia, Pozzilli, Carlo, Selmaj, Krzysztof W., Scott, Thomas F., Chung, Luke, Daizadeh, Nadia, Afsar, Salman and Van Wijmeersch, Bart (2019). Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study). 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2019 Conference Publication Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)Pelletier, Daniel, Arnold, Douglas L., Boyko, Alexey N., Comi, Giancarlo, Hartung, Hans-Peter, Havrdova, Eva Kubala, Inshasi, Jihad Said, McCombe, Pamela, Nakamura, Kunio, Oreja-Guevara, Celia, Pozzilli, Carlo, Selmaj, Krzysztof W., Scott, Thomas F., Chung, Luke, Daizadeh, Nadia, Afsar, Salman and Van Wijmeersch, Bart (2019). Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study). AAN 71st Annual Meeting, Philadelphia, PA United States, 4-10 May 2019. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.92.15_supplement.p3.2-037 |
|
2019 Conference Publication Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorderKunchok, Amy, Malpas, Charles, Nytrova, Petra, Havrdova, Eva, Alroughani, Raed, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit, Ozakbas, Serkan, Olascoaga Urtaza, Francisco Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, McCombe, Pamela, Csepany, Tunde, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse ... Kalincik, Tomas (2019). Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia, PA, United States, 4-10 May 2019. Philadelphia, PA, United States: Wolters Kluwer Health. |
|
2019 Conference Publication Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing DataMcCombe, P., Vukusic, S., Coyle, P. K., Jurgensen, S., Truffinet, P., Benamor, M., Poole, E., Chavin, J. and Chambers, C. (2019). Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data. Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage. |
|
2019 Conference Publication Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 yearsCelius, E. G., Achiron, A., Compston, D. A. S., Derwenskus, J., Devonshire, V., Hellwig, K., Hutton, G. J., McCombe, P., Moore, M., Oh, J., Simm, R. F., Sousa, L., Vincent, S. G., Chung, L., Daizadeh, N., Mitchell, C. and Rog, D. (2019). Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2019 Conference Publication Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS)Lechner-Scott, Jeannette, Maltby, Vicky, Lyndon, Amanda, Monif, Mastura, Kilpatrick, Trevor, Butzkueven, Helmut, Taylor, Bruce, McCombe, Pamela, Hodgkinson, Suzanne, Fabis-Pedrini, Marzena, Kermode, Allan, Barnett, Michael and Kalincik, Tomas (2019). Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS). Annual Scientific Meeting of the Australian and New Zealand Association of Neurologists (ANZAN), Sydney, Australia, May 21-24, 2019. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2019-anzan.119 |
|
2019 Conference Publication Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)McCombe, P., Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H-P., Havrdova, E. K., Inshasi, J. S., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study). Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage. |
|
2019 Conference Publication Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study)Montalban, X., Arnold, D. L., Boyko, A. N., Comi, G., Hartung, H.-P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Scott, T. F., Vieira Alves Leon, S., Chung, L., Daizadeh, N., Afsar, S. and Selmaj, K. W. (2019). Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study). 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2018 Conference Publication Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registrySpelman, T., Harvrdova, E. K., Horakova, D., Izquierdo, G., Kalincik, T., Lugaresi, A., Onofrj, M., Duquette, P., Girard, M., Prat, A., Grammond, P., Grand'Maison, F., Granella, F., Lechner-Scott, J., Sola, P., Ferrero, D., Sa, M. J., Terzi, M., Ozakbas, S., Van Pesch, V., Van Wijmeersch, B., Boz, C., Karabudak, R., Cartechini, E., McCombe, P. and Butzkueven, H. (2018). Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
